82. Support development of optimized laboratory networks and introduction of new, innovative solutions to the marketplace.
83. Develop additional assays for current laboratory technologies, including TB, hepatitis, and HPV to support multiplex testing.
84. Closer collaboration with countries, partners, and donors for better forecasting.
85. Include the EID indeterminate range into new systems.
87. Support development of key performance indicators.
86. Provide pricing transparency through Global Fund collaboration.
83. Already have Hepatitis and HPV and working to submit to WHO PQ. MTB and MAI now available and Rif INH should be available this quarter. Roche has expanded the Global Access Program to include its tests for Tuberculosis, hepatitis and HPV for cervical cancer screening. All of these tests run on cobas 6800 and 8800, which is also used for HIV viral load and EID testing. Submitted its HPV tests for WHO PQ, and they have been accepted for approval via the abridged route.
84.Collaboration for better forecasting is ongoing; have had meetings with Global Fund and USAID/Chemonics; would like WHO to address minimum shelf-life requirements in a timely fashion
85. EID indeterminate range - exists already on Cobas system; discussing with WHO on how to implement on newer platforms
86. Several discussions with Global Fund to break down the pricing, including the distributor piece, for the countries that the GF procures for, and pricing transparency was featured in PEPFAR's RFP
22. Make every effort to stay in the EID market to ensure there is a sufficient testing capacity to reach and maintain accelerated Fast Track targets (95% of HEI tested by 2020 and beyond).
23. Ensure consistent reagent pricing across partners within countries and within regions, and provide a transparent breakdown of pricing for the products and services sold.
24. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, ideally all-inclusive pricing models.
25. Provide service level agreements that clearly spell out key performance indicators POC, near POC, and high-throughput laboratory instruments, including target up-times and failure rate threshold (with consideration for different causes), plus a mitigation plan when the threshold is exceeded.
26. Consider the inclusion of a clinical indeterminate range in test result reports for more accurate diagnosis of infants per WHO guidelines.
27. Rapidly communicate stock shortages with major buyers and work on joint mitigation strategies.